

Time: 8 am to 5 pm.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Krish Krishnan, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892, (301) 435-1041.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8-9, 2001

Time: 8:30 am to 5:30 pm.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

Contact Person: Angela M. Pattatucci-Aragon, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5220, MSC 7852, Bethesda, MD 20892, (301) 435-1775.

Name of Committee: Center for Scientific Review Special Emphasis Panel, ZRG1 TMP (01).

Date: November 8-9, 2001

Time: 8:30 am to 5 pm.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Jean Hickman, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4194, MSC 7808, Bethesda, MD 20892, (301) 435-1146.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8-9, 2001.

Time: 9 am to 5:30 pm.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn—Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Contact Person: Yvette M. Davis, VMD, MPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, 301-435-0906.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8, 2001.

Time: 11 am to 12:30 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Everett E. Sinnett, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2178, MSC 7818, Bethesda, MD 20892, (301) 435-1016, sinnett@nih.gov

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8, 2001.

Time: 2 pm to 4 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Mary Sue Krause, MED, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC, Bethesda, MD 20892, 301-435-0902, mkrause@csr.nih.gov

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8, 2001.

Time: 2:15 to 3:30 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Alec S. Liacouras, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5154, MSC 7842, Bethesda, MD 20892, (301) 435-1740.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8, 2001.

Time: 3:30 pm to 5 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Ann A. Jerkins, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6154, MSC 7892, Bethesda, MD 20892, (301) 435-4514.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 8, 2001.

Time: 12:30 pm to 1:30 pm.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Mary Sue Krause, MED, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC, Bethesda, MD 20892, 301-435-0902, mkrause@csr.nih.gov

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: November 9, 2001.

Time: 8:30 am to 4:30 pm.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Hotel, The Chevy Chase Pavilion, 4300 Military Road NW, Wisconsin at Western Avenue, Washington, DC 20015.

Contact Person: Calbert A. Laing, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4210, MSC 7812, Bethesda, MD 20892, 301-435-1221, laingc@csr.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 16, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-26616 Filed 10-22-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Availability of Expert Panel Reports National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), Center for the Evaluation of Risks to Human Reproduction (CERHR), announces:

(1) Availability of the Draft Expert Panel Reports on 1-Bromopropane and 2-Bromopropane—Public comments are solicited on these draft reports and the deadline for written comments is November 23, 2001.

(2) Bromopropane Expert Panel Meeting scheduled for December 5-7, 2001—The meeting is open to the public and will be held at the Hilton Washington-Dulles Airport Hotel, Herndon, VA.

Background

The NTP and the NIEHS established the NTP CERHR [Federal Register, December 14, 1998 (Volume 63, Number 239, page 68782)] in June 1998. The purpose of the Center is to provide scientifically-based, uniform assessments of the potential for adverse effects on reproduction and development caused by agents to which humans may be exposed. Expert panels conduct scientific evaluations of agents selected by the Center in public forums. Additional details about CERHR are provided below (see Additional Information about CERHR evaluations).

The agents currently under evaluation are 1-bromopropane (CASRN: 106-94-5) and 2-bromopropane (CASRN: 75-26-3). 1-Bromopropane is used as a cleaning solvent; as a solvent vehicle in spray adhesives; as a solvent for fats, waxes, or resins; and as an intermediate in the synthesis of other compounds. 2-Bromopropane is used in the synthesis of pharmaceuticals, dyes, and other compounds and is present as a contaminant in 1-bromopropane. Bromopropanes are being considered as replacement chemicals for ozone-depleting chemicals such as hydrochlorofluorocarbons and chlorinated solvents. The scientific database on these chemicals includes studies on neurotoxicity, reproductive toxicity, and occupational exposures. 2-

Bromopropane is reported to be a reproductive toxicant in humans.

Draft Expert Panel Reports on 1-Bromopropane and 2-Bromopropane Available

The Draft Expert Panel Report is composed of the following sections:

- 1.0 Chemistry, Use, and Human Exposure
- 2.0 General Toxicological and Biological Effects
- 3.0 Developmental Toxicity Data
- 4.0 Reproductive Toxicity Data
- 5.0 Summary, Conclusions, and Critical Data Needs

Sections 1–4 will be available to the public by October 10, 2001. Copies can be obtained electronically on the CERHR web site (<http://cerhr.niehs.nih.gov>) or in hard copy by contacting Dr. Michael Shelby, Director CERHR (NIEHS, 79 T.W. Alexander Drive, Building 4401, Room 103, P.O. Box 12233, MD EC-32, Research Triangle Park, NC 27709, Phone: (919) 541-3455; Fax: (919) 316-4511; shelby@niehs.nih.gov).

Request for Written Comments on Draft Expert Panel Reports

The CERHR invites written public comments on Sections 1–4 of the Draft Expert Panel Reports on 1-bromopropane and 2-bromopropane. Comments can be submitted in hard copy or electronic format and must be received by the Center by November 23, 2001. These comments will be distributed to CERHR staff and the Bromopropane Expert Panel for consideration in revising the draft report and in preparing for the Bromopropane Expert Panel Meeting (see below). These comments should be sent to Dr. Michael Shelby at the address provided above. Persons submitting written comments are asked to include their name and contact information (affiliation, mailing address, phone, fax, e-mail, and sponsoring organization, if any).

Expert Panel Will Review 1-Bromopropane and 2-Bromopropane

An expert panel (the Panel) of independent scientists selected for their scientific expertise in reproductive and developmental toxicology and other relevant areas of science are conducting this review. The roster of experts follows:

Bromopropane Expert Panel (Name and Affiliation)

Kim Boekelheide, MD, PhD [Chair]
Brown University, Providence, RI
Cynthia F. Bearer, MD, PhD Case
Western Reserve, Cleveland, OH
Sally Perreault Darney, PhD U.S. EPA,
Research Triangle Park, NC

George P. Daston, PhD Procter & Gamble Co., Cincinnati, OH
Raymond M. David, PhD Eastman
Kodak Company, Rochester, NY
Ulrike Luderer, MD, PhD University of
California-Irvine, Irvine, CA
Andrew F. Olshan, PhD University of
North Carolina, Chapel Hill, NC
Wayne T. Sanderson, PhD, CIH
NIOSH, Cincinnati, OH
Calvin C. Willhite, PhD DTSC, State of
California, Berkeley, CA
Susan Woskie, PhD University of
Massachusetts-Lowell, Lowell, MA

Public Meeting of the Bromopropane Expert Panel

This meeting is open to the public and attendance is limited only by the availability of space. The meeting will take place on December 5–7, 2001, in the Solarium of the Hilton Washington-Dulles Airport Hotel, 13869 Park Center Road, Herndon, VA 20171, Phone (703) 478-2900, Fax (703) 478-9286.

Preliminary Meeting Agenda

The meeting begins each day at 8:30 a.m. It is anticipated that each day there will be a lunch break from 12–1 p.m. and the meeting will adjourn between 5 and 6 p.m. .

December 5, 2001 (8:30 a.m.)

Opening comments

Public comment session

- The Panel will receive comments from the public (up to seven minutes per speaker; details are given below).

Review of Sections 1–4 of the Draft Expert Panel Report on 1-Bromopropane and 2-Bromopropane

Discussion of Section 5.0 Summary, Conclusions, and Critical Data Needs

December 6, 2001 (8:30 a.m.)

Discussion of Section 5.0 Summary, Conclusions, and Critical Data Needs

Preparation of draft summaries and conclusion statements

December 7, 2001 (8:30 a.m.)

Presentation, discussion of, and agreement on summaries and conclusions

Closing comments

Oral Public Comments Can Be Presented at the Expert Panel Meeting

Time is set aside on December 5 for the presentation of oral public comments at the Bromopropane Expert Panel Meeting. To facilitate planning of this meeting, those persons wishing to make oral public comments are asked to contact the CERHR Director by November 26 [Dr. Michael Shelby, NIEHS, 79 T.W. Alexander Drive,

Building 4401, Room 103, P.O. Box 12233, MD EC-32, Research Triangle Park, NC 27709, Phone: (919) 541-3455; Fax (919) 316-4511; shelby@niehs.nih.gov]. Seven minutes will be available for each speaker (one speaker per organization). When registering to comment orally, please provide your name, affiliation, mailing address, phone, fax, e-mail and sponsoring organization (if any). If possible, also send a copy of the statement or talking points to CERHR by November 26. This information will be provided to the expert panel, to assist the panel in identifying issues for discussion, and will be noted in the meeting record. Registration for presentation of oral comments will also be available at the meeting on December 5 (7:30–8:30 a.m.). Those persons registering at the meeting are asked to bring 20 copies of their statement or talking points.

In lieu of making an oral presentation at the meeting, the public is invited to submit a written statement to CERHR by November 26. This statement will be distributed to CERHR staff and the Bromopropane Expert Panel and noted in the meeting record.

Post-Meeting Public Comments

Following the Bromopropane Expert Panel Meeting and completion of the Expert Panel Report, public comment will be solicited. This solicitation will be announced in a future **Federal Register** notice.

For other questions about the Draft Report on 1-Bromopropane and 2-Bromopropane or the Bromopropane Expert Panel Meeting, contact the CERHR Director [contact information provided above].

Additional Information About CERHR Evaluations

CERHR invites the nomination of agents for review or scientists for its expert registry. Information about CERHR and the nomination process can be obtained from its homepage (<http://cerhr.niehs.nih.gov>) or by contacting the Center Director [contact information provided above]. The Center selects chemicals for evaluation based upon several factors including production volume, extent of human exposure, public concern, and published evidence of reproductive or developmental toxicity.

CERHR follows a formal, multi-step process for review and evaluation of selected chemicals. The formal evaluation process is outlined in the **Federal Register** notice July 16, 2001 (Volume 66, Number 136, pages 37047–37048) and on the CERHR web site

under "About CERHR". Briefly, the Center establishes an expert panel to review and evaluate the scientific evidence on the selected chemical(s), to receive public comments, and to prepare a report on the chemical(s). This draft expert panel report is made publicly available for comment, both through the CERHR web site and upon request from CERHR, and an expert panel meeting is held to discuss and evaluate the draft report. Following the expert panel meeting and completion of the expert panel report, public comment is solicited again. After this public comment period ends, the NTP staff prepares a NTP center report on the evaluated chemical(s) that integrates background information on the chemical(s), findings of the expert panel, and a discussion of any additional, recent studies. The NTP center report includes all public comments received on the expert panel

report. The final NTP center report is made publicly available and distributed to interested stakeholders and to appropriate regulatory, health, and research agencies.

Dated: October 3, 2001.

Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 01-26621 Filed 10-22-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2002 Funding Opportunities

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of funding availability.

SUMMARY: The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment (CSAT) announces the availability of FY 2001 funds for grants for the following activity. This notice is not a complete description of the activity; potential applicants must obtain a copy of the Guidance for Applicants (GFA), including Part I, Grants to Support the Accreditation of Opioid Treatment Programs (OTPs), and Part II, General Policies and Procedures Applicable to all SAMHSA Applications for Discretionary Grants and Cooperative Agreements, before preparing and submitting an application.

Activity	Application deadline	Est. funds FY 2001	Est. No. of awards	Project period
Grants to Support Accreditation of Opioid Treatment Programs.	December 4, 2001	\$1.6 million	-8	3 years

The actual amount available for the award may vary, depending on unanticipated program requirements and the number and quality of applications received. FY 2002 funds for the activity discussed in this announcement were appropriated by the Congress under Public Law No. 106-310. SAMHSA's policies and procedures for peer review and Advisory Council review of grant and cooperative agreement applications were published in the **Federal Register** (Vol. 58, No. 126) on July 2, 1993.

General Instructions

Applicants must use application form PHS 5161-1 (Rev. 7/00). The application kit contains the two-part application materials (complete programmatic guidance and instructions for preparing and submitting applications), the PHS 5161-1 which includes Standard Form 424 (Face Page), and other documentation and forms. Application kits may be obtained from: National Clearinghouse for Alcohol and Drug Information (NCADI), P.O. Box 2345, Rockville, MD 20847-2345, Telephone: 1-800-729-6686.

The PHS 5161-1 application form and the full text of the activity are also available electronically via SAMHSA's World Wide Web homepage: <http://www.samhsa.gov>.

When requesting an application kit, the applicant must specify the particular

activity for which detailed information is desired. All information necessary to apply, including where to submit applications and application deadline instructions, are included in the application kit.

Purpose: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT) announces the availability of fiscal year (FY) 2002 funds for grants to partially subsidize the cost of accreditation of Opioid Treatment Programs (OTPs). The goal of these grants is to reduce the costs of basic accreditation education and accreditation surveys (site visits) for OTPs participating in the accreditation process pursuant to Title 42 of the Code of Federal Regulations (CFR), part 8.

Eligibility: Under Federal regulations, the final rule on Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction (42 CFR part 8), only private nonprofit organizations or State governmental entities, or political subdivisions thereof, which are approved by SAMHSA pursuant to that regulation, may accredit opioid treatment programs. Therefore, awards under this grant program will be made only to organizations that have been approved by SAMHSA as accreditation bodies.

SAMHSA intends to make awards under this program as soon as possible; however, all grant awards must be made

prior to September 30, 2002. Therefore, any organization that has not yet applied to SAMHSA for approval as an accreditation body is urged to do so as soon as possible, as review and approval of these applications takes some time.

Such organizations may apply for funding under this grant program prior to, simultaneously with, or after they submit their application for approval as an accreditation body, so long as they submit their application for funding prior to the application due date of December 4, 2001. However, an application for a grant under this program will be considered for funding only after the applicant has been approved as an accrediting body, if such approval occurs prior to September 30, 2002.

Availability of Funds: In FY 2002, approximately \$1,600,000 will be available for the total costs (direct and indirect) of 4 to 8 awards.* Awards will

*This program is being announced prior to the full annual appropriation for fiscal year (FY) 2002 for the Substance Abuse and Mental Health Services Administration's (SAMHSA) programs. Applications are invited based on the assumption that sufficient funds will be appropriated for FY 2002 to permit funding of a reasonable number of applications being hereby solicited. All applicants are reminded, however, that we cannot guarantee sufficient funds will be appropriated to permit SAMHSA to fund any applications. Questions regarding the status of the appropriation of funds should be directed to the Program Contact listed under the "How to Get Help" section in the grant announcement.